Publish in this journal
Journal Information
Vol. 13. Issue 5.
Pages 294-296 (September - October 2017)
Share
Share
Download PDF
More article options
ePub
Visits
1051
Vol. 13. Issue 5.
Pages 294-296 (September - October 2017)
Case Report
DOI: 10.1016/j.reumae.2017.04.001
Relapsed Hydroxychloroquine Induced Thrombocytopenia in Systemic Lupus Erythematosus Patient
Trombocitopenia recurrente inducida por hidroxicloroquina en ausencia de actividad del lupus eritematoso sistémico
Visits
1051
Vanesa Antón Vázqueza,
Corresponding author
vanesa.anton.v@gmail.com

Corresponding author.
, Luis Pascuala, Héctor Corominas Maciasb, Isabel Giménez Torrecillac
a Servicio de Medicina Interna, Hospital Moisès Broggi, Sant Joan Despí, Barcelona, Spain
b Servicio de Reumatología, Hospital Moisès Broggi, Sant Joan Despí, Barcelona, Spain
c Servicio de Nefrología, Hospital Moisès Broggi, Sant Joan Despí, Barcelona, Spain
This item has received
1051
Visits
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (1)
Table 1. Platelet Count, White Blood Cells, Red Blood Cells, Anti-DNA and Complement According to Exposure to and Interruption of Hydroxychloroquine (HCQ).
Abstract

Hydroxychloroquine is used in the long-term therapy of systemic lupus erythematosus (SLE). Although considered to be a safe treatment, side effects have been documented. An uncommon side effect is thrombocytopenia. In order to establish the diagnosis of thrombocytopenia secondary to Hydroxychloroquine, non-pharmacological causes must be ruled out and it is necessary to determine a recurrence after re-exposure to the drug. We present one case of severe thrombocytopenia occurring in a patient with SLE undergoing treatment with Hydroxychloroquine.

Keywords:
Hydroxychloroquine
Thrombocytopenia
Systemic lupus erythematosus
Resumen

La hidroxicloroquina es un fármaco antimalárico, empleado como terapia a largo plazo en el lupus eritematoso sistémico (LES). A pesar de considerarse un tratamiento seguro, existen efectos adversos descritos. Uno muy infrecuente es la trombocitopenia. Para establecer el diagnóstico de trombocitopenia causada por hidroxicloroquina es necesario descartar otras causas no farmacológicas y objetivar la recurrencia tras la reexposición al fármaco. Presentamos un caso de trombocitopenia severa en un paciente con LES durante el tratamiento con hidroxicloroquina.

Palabras clave:
Hidroxicloroquina
Trombocitopenia
Lupus eritematoso sistémico

Article

These are the options to access the full texts of the publication Reumatología Clínica (English Edition)
Member
If you are member of Sociedad Española de Reumatología (SER) or the Colegio Mexicano de Reumatología (CMR):
Please go to the member area of SER or CMR and log in.
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Reumatología Clínica (English Edition)

Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Email
Idiomas
Reumatología Clínica (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.